Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$1.63 - $3.46 $29,692 - $63,027
-18,216 Reduced 99.89%
20 $0
Q1 2022

May 16, 2022

SELL
$2.66 - $6.49 $2,896 - $7,067
-1,089 Reduced 5.64%
18,236 $56,000
Q4 2021

Feb 14, 2022

BUY
$6.24 - $10.2 $32,547 - $53,203
5,216 Added 36.97%
19,325 $123,000
Q3 2021

Nov 12, 2021

BUY
$9.73 - $15.52 $2,919 - $4,656
300 Added 2.17%
14,109 $140,000
Q2 2021

Aug 16, 2021

SELL
$12.44 - $19.45 $4,926 - $7,702
-396 Reduced 2.79%
13,809 $182,000
Q1 2021

May 14, 2021

SELL
$16.24 - $29.83 $30,758 - $56,498
-1,894 Reduced 11.76%
14,205 $249,000
Q4 2020

Feb 12, 2021

BUY
$14.28 - $29.73 $229,893 - $478,623
16,099 New
16,099 $412,000

Others Institutions Holding PASG

About Passage BIO, Inc.


  • Ticker PASG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,463,200
  • Market Cap $32.1M
  • Description
  • Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...
More about PASG
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.